Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 45 countries primarily in Asia, Central and South America, the Middle East, etc. The company was founded in 1958 and is headquartered in Seoul, South Korea.
Daewon Pharmaceutical Dividend Announcement
• Daewon Pharmaceutical announced a annually dividend of ₩300.00 per ordinary share which will be made payable on 2024-04-19. Ex dividend date: 2023-12-27
• Daewon Pharmaceutical annual dividend for 2023 was ₩300.00
• Daewon Pharmaceutical's trailing twelve-month (TTM) dividend yield is 2.1%
• Daewon Pharmaceutical's payout ratio for the trailing twelve months (TTM) is 43.29%
• Daewon Pharmaceutical's dividend growth over the last five years (2018-2023) was 5.15% year
• Daewon Pharmaceutical's dividend growth over the last ten years (2013-2023) was 14.87% year
Daewon Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2023-12-27 | ₩300.00 | annually | 2024-04-19 |
2022-12-28 | ₩350.00 | annually | 2023-04-21 |
2021-12-29 | ₩200.00 | annually | 2022-04-22 |
2020-12-29 | ₩152.38 | annually | 2021-04-16 |
2019-12-27 | ₩240.41 | annually | 2020-04-17 |
2018-12-27 | ₩233.40 | annually | 2019-04-12 |
2017-12-27 | ₩222.29 | annually | 2018-04-13 |
2016-12-28 | ₩215.82 | annually | |
2015-12-29 | ₩161.18 | annually | |
2014-12-29 | ₩115.13 | annually | |
2013-12-27 | ₩75.00 | annually | |
2012-12-27 | ₩50.00 | annually |
Daewon Pharmaceutical Dividend per year
Daewon Pharmaceutical Dividend growth
Daewon Pharmaceutical Dividend Yield
Daewon Pharmaceutical current trailing twelve-month (TTM) dividend yield is 2.1%. Interested in purchasing Daewon Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Daewon Pharmaceutical Financial Ratios
Daewon Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Daewon Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Daewon Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Daewon Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Daewon Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Daewon Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Daewon Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Daewon Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Daewon Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Daewon Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Daewon Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Daewon Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.